Key result
Pediatric HF drug trials face significant challenges requiring new structures for development and implementation.
Why the study?
The evidence to guide therapy for pediatric heart failure is limited due to significant challenges in performing well-designed drug trials in this population.
Highlights the significant challenges in conducting well-designed drug trials for pediatric heart failure and proposes structures for future development.
Answers are grounded in this paper and cite their sources.
Trial design barriers limit pediatric HF drug development; review proposes structures but leaves optimal frameworks open.
The evidence available from which to guide therapy for pediatric heart failure is limited. Although there are many reasons for this, the greatest obstacles in developing this evidence base are due to the significant challenges inherent in performing well-designed drug trials in pediatric heart failure. This perspective will define many of these obstacles and will propose potential structures for the development and implementation of drug trials in pediatric heart failure.
No takes yet. Share an insight, caveat, or question.
Robert E. Shaddy (2006) conducted a review in Pediatric heart failure. Drug trials was evaluated. Significant challenges exist in performing well-designed drug trials in pediatric heart failure, requiring new structures for their development and implementation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: